After losing 3,500 employees in April—19% of its workforce due to congressional budget cuts—the FDA is now struggling to meet ...

LENZ Therapeutics previously licensed Greater China rights to CORXEL for the development and commercialization of LNZ100 in April 2022.

Submission of NDA for LNZ100 in China by CORXEL Pharmaceuticals results in achievement of first milestone due to LENZ under the Development and Commercialization Agreement ...

Shares of Zymeworks were higher after the Food and Drug Administration cleared the company's investigational new drug application for its treatment for liver cancer. The stock rose 8.5%, to $14.46, in ...

Alembic Pharmaceuticals on Monday said it has received final approval from the US health regulator for its generic version of ...

US FDA extends review period for Bayer’s NDA for elinzanetant to treat moderate to severe VMS due to menopause: Berlin Monday, July 28, 2025, 16:00 Hrs [IST] Bayer announced tha ...

Second antibody-drug conjugate (ADC) to progress into clinical development utilizing our proprietary payload and optimized antibodyPreclinical results demonstrate strong anti-tumor activity and favora ...

For example, a cancer patient can now buy a locally produced immunity boosting drug for Tk 7,000-8,000 per pre-filled syringe, while the imported version would cost Tk 85,000-95,000. Experts note that ...

This submission represents the third accepted application for ivonescimab in China, following previous filings for its combination therapy in EGFR-TKI resistant locally advanced or metastatic ...

Each year, the FDA approves a wide range of medications that help shape the future of medicine in the U.S. These include ...

Stocks like Kotak Mahindra Bank, Central Depository Services, Balkrishna Industries, Orient Cement, Tata Chemicals, Poonawalla Fincorp, VA Tech Wabag, RITES, Sigachi Industries, and Ola Electric ...